LeMaitre Vascular, Inc. (NASDAQ:LMAT) Insider Trent G. Kamke Sells 2,009 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $81.91 on Friday. The business’s fifty day moving average price is $95.21 and its two-hundred day moving average price is $94.63. The company has a market capitalization of $1.85 billion, a P/E ratio of 44.76, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This represents a $0.80 annualized dividend and a yield of 0.98%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s payout ratio is presently 41.24%.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its stake in shares of LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after buying an additional 4,330 shares in the last quarter. Townsquare Capital LLC raised its stake in shares of LeMaitre Vascular by 38.0% in the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after buying an additional 13,210 shares in the last quarter. Barclays PLC raised its stake in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after buying an additional 29,180 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $567,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after buying an additional 11,395 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price for the company. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.